Oxford Biomedica (otc) (GB:OXB) has released an update.
Oxford Biomedica, a leading cell and gene therapy CDMO, disclosed that as of April 30, 2024, their total issued share capital consists of 100,000,296 ordinary shares, with the same number of voting rights available. This figure is crucial for shareholders to determine their notification obligations regarding shareholding changes as per the FCA’s guidance. The company highlights its extensive experience in viral vectors and partnerships with major pharmaceutical and biotech firms, underscoring its global impact in delivering life-changing therapies.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
